Filing Analysis
Cocrystal Pharma appointed James Sapirstein as Chief Executive Officer effective June 3, 2026. He replaces the previous Co-CEO structure consisting of Sam Lee and James Martin.
🚩 Red Flags
- Shift from a Co-CEO leadership structure to a single CEO often indicates a strategic pivot or a need for centralized decision-making following previous instability or lack of progress.
📋 Key Facts
- James Sapirstein appointed as CEO on June 3, 2026.
- Compensation includes a base salary of $265,000 and a performance bonus of 50% of base salary.
- Initial equity grant of 10-year stock options for 235,000 shares at an exercise price of $1.05.
- Potential for an additional grant of 235,000 options on the six-month anniversary of start date, subject to performance and committee approval.
- Mr. Sapirstein previously served as CEO of Entero Therapeutics, Inc. (Nasdaq: ENTO) from 2019 to 2025.
- Former Co-CEOs Sam Lee and James Martin transition to President/CSO and CFO roles, respectively.
Cocrystal Pharma, Inc. announced the appointment of James Sapirstein as the company's new Chief Executive Officer on June 3, 2026.
📋 Key Facts
- James Sapirstein appointed as Chief Executive Officer
- Announcement made via press release on June 3, 2026
- Filing signed by James Martin, Chief Financial Officer
Cocrystal Pharma, Inc. (COCP) filed an 8-K to furnish a press release dated May 26, 2026, regarding its novel direct-acting antivirals.
📋 Key Facts
- The filing is a Regulation FD disclosure under Item 7.01.
- The subject of the press release is the company's novel direct-acting antivirals.
- The press release is attached as Exhibit 99.1.
Cocrystal Pharma announced that its oral protease inhibitor, CDI-988, was featured in an oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026). The presentation focused on the drug's mechanism of action and its current clinical advancement.
📋 Key Facts
- Oral presentation at ICAR 2026 in Prague, Czech Republic on April 30, 2026.
- Featured drug candidate: CDI-988, an oral protease inhibitor.
- Presentation covered mechanism of action and clinical progress.
Cocrystal Pharma announced that the FDA has granted Fast Track designation to its oral antiviral candidate, CDI-988, for the treatment and prophylaxis of norovirus infection. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill unmet medical needs.
📋 Key Facts
- FDA granted Fast Track designation to CDI-988 on April 2, 2026.
- CDI-988 is an oral, direct-acting protease inhibitor candidate.
- The drug is being developed for both treatment and prophylaxis of norovirus infection.
- The company claims CDI-988 is the first oral antiviral candidate for this specific indication.
Cocrystal Pharma, Inc. (COCP) filed an 8-K to announce its financial results for the fiscal year ended December 31, 2025. The filing includes a press release with business updates and financial performance metrics.
🚩 Red Flags
- Clerical inconsistency: The body text of Item 2.02 incorrectly states the press release was issued on November 14, 2025, for the fiscal year ended December 31, 2025, which is chronologically impossible.
📋 Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The press release (Exhibit 99.1) is dated March 31, 2026.
- The report was signed by James Martin, who holds the dual role of Co-Chief Executive Officer and Chief Financial Officer.
- The filing includes a clerical error in the Item 2.02 text, which incorrectly references a November 14, 2025 date for the year-end results announcement.
Cocrystal Pharma, Inc. reported the passing of Dr. Anthony Japour, a member of the company's Board of Directors, on March 10, 2026.
📋 Key Facts
- The company was notified of Dr. Anthony Japour's death on March 10, 2026.
- Dr. Japour served as a member of the Board of Directors.
- The filing was made under Item 5.02 of Form 8-K.
Cocrystal Pharma, Inc. issued a press release on March 9, 2026, providing a clinical update on its Phase 1b norovirus challenge study. The study is evaluating the drug candidate CDI-988 for its efficacy as both a preventive and treatment for norovirus infections.
📋 Key Facts
- The filing was made under Item 7.01 Regulation FD Disclosure on March 9, 2026.
- The update concerns the Phase 1b norovirus challenge study for drug candidate CDI-988.
- CDI-988 is being developed as both a preventive and a treatment for norovirus.
- The report was signed by James Martin, who serves as both Co-Chief Executive Officer and Chief Financial Officer.
Cocrystal Pharma disclosed via Regulation FD that its oral norovirus protease inhibitor CDI-988 will be featured at the International Society for Antiviral Research Conference (ICAR) 2026 in Prague, April 27–May 1, 2026. This is a routine scientific conference presentation announcement with no material financial or structural changes to the company.
🚩 Red Flags
- James Martin holds dual role as Co-CEO and CFO, concentrating executive authority
- Reg FD disclosure is 'furnished' not 'filed,' offering limited investor protection
📋 Key Facts
- CDI-988 is described as the Company's 'first oral norovirus protease inhibitor'
- Drug candidate will be featured at ICAR 2026, held April 27–May 1, 2026 in Prague, Czech Republic
- Filing signed by James Martin, Co-Chief Executive Officer and Chief Financial Officer (dual role)
- Company is incorporated in Delaware, headquartered in Bothell, WA
- Trades on Nasdaq Capital Market under ticker COCP
- Information furnished under Item 7.01 (not 'filed'), limiting liability exposure